

FORM PTO-1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ST00001A-US	SERIAL NO. 09/752,926
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Mary et al	RECEIVED AUG 01 2002
(Use several sheets if necessary)		FILING DATE 2 January 2001	GROUP 1614 162 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	*	DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
		9	8	5	3	8	3	3	12/3/98	WO					YES	NO
LCM		B1	9	8	5	3	8	3	3	12/3/98	WO				Yes (Ref. A2)	
LCM		B2	9	8	5	3	8	3	4	12/3/98	WO	abstract only			Yes (+)	X
LCM		B3	9	4	0	8	5	9	5	4/28/94	WO					

+ - Abstract attached, full text is available in file of corresponding U. S. Application No. 60/085,848.

OTHER DOCUMENTS

EXAMINER INITIALS	*	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
LCM	C1	LI ET AL; Posttreatment with low molecular weight heparin reduces brain edema and infarct volume in rats subjected to thrombotic middle cerebral artery occlusion; BRAIN RES.; Vol. 801; No. 1-2; pp. 220-223 (1998)
LCM	C2	HILLBOM ET AL; Comparison of the efficacy of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of deep vein thrombosis in patients with a acute ischemic stroke; BLOOD; Vol. 94; No. 10 suppl, pt1; pp. 183a; (Nov. 15, 1999)
LCM	C3	SAMANA ET AL; Acute ischemic stroke and heparin treatments; THROMB. HAEMOSTASIS; Vol. 78, No. 1; pp. 173-179; (1997)
LCM	C4	GORDON ET AL; Low molecular weight heparins and heparinoids and their use in acute or progressing ischemic stroke; CLIN. NEUROPHARMACOL.; Vol. 13; No. 6; pp. 522-544; (1990)
LCM	C5	KAY ET AL; Low molecular weight heparin for the treatment of acute ischemic stroke; NEW ENGLAND J. MED.; Vol. 333; No. 24; pp. 1588-1593; (1995)
	**C6	BATH ET AL; Low molecular weight heparin in acute stroke; EXPERT OPINION INVEST. DRUGS; Vol. 7; No. 8; pp. 1323-1330; (1998)
LCM	C7	HARENBERG ET AL; Enoxaparin is superior to unfractionated heparin in the prevention of thromboembolic events in medical patients at increased thromboembolic risk; BLOOD; Vol. 94; No. 10pt1.suppl.1; pp. 399a, (1999)
	**C8	TAIST INVESTIGATORS; Tinzaparin in acute ischemic stroke trial (TAIST); STROKE; Vol. 30; No. 1 pp. 163; (1999-01)
LCM	C9	CHEMICAL ABSTRACTS; Low-mol.-wt. Heparin in treatment of acute cerebral infarction; Vol. 127; No. 24; Abstract No. 326219z; pp. 54; (1997)
LCM	C10	CHEMICAL ABSTRACTS; Clinical study on low-mol.-wt. heparin (LLMWH) for treatment of acute cerebral infarction; Vol. 130; No. 1; Abstract No. 336b; pp. 44; (1999)
LCM	C11	DAHL ET AL; Dalteparin in acute ischemic cerebrovascular disease: a safety study; CEREBROVASCULAR DISEASES; Vol. 7, No. 1; pp. 28-33; (1997)

FORM PTO-1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ST00001A-US	SERIAL NO. 09/752,926
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Mary et al	RECEIVED
(Use several sheets if necessary)		FILING DATE 2 January 2001	GROUP 1614 1623
O P T E JUL 3 0 2002		AUG 01 2002 TECH CENTER 1600/2900	

OTHER DOCUMENTS

EXAMINER INITIALS	*	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
LCM	C12	PRINS ET AL; Prophylaxis of deep venous thrombosis with a low molecular weight heprin (Kabi 2165/Fagmin) in stroke patients; HAEMOSTASIS; Vol. 19, No. 5; pp. 245-250; (1989)
LCM	C13	KAY ET AL; Pilto study of low molecular weight heparin in the treatment of acute ischemic stroke; STROKE; Vol. 25; No. 3; pp. 684-685; (1994-03)
LCM	C14	RYU ET AL; Heparin reduces neurological impairment after cerebral air embolism in the rabbit; STROKE; Vol. 27; No. 2; pp. 303-310; (1996)
LCM	C15	STULLKEN ET AL; The effects o heparin on recovery from ischemic brain infarcts in cats; ANESTH. ANALG.; Vol. 55; No. 5; pp. 683-687; (1976)
	**C16	XANAKA ET AL; Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia. II. Dose-response effect and the therapeutic window; J. NEUROSURG.; Vol. 85; No. 6; pp. 1108-1112; (1996)
	**C17	AGG. TURPIE ET AL; THE LANCET; pp. 523-526; (1987)
	**C18	A. ELIAS ET AL; La Revue de Medecine Interne; 1, Vol. XI; pp. 95-98 (1990)

EXAMINER	<i>Lugh M</i>	DATE CONSIDERED	<i>9-6-02</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Note: Asterisk (*) item(s) have been previously cited in a related application(s) either by the applicant or by the USPTO and therefore copies of the reference(s) are not being submitted.			